List of Arcus Biosciences patents

List of Arcus Biosciences patents

List of CytomX Therapeutics patents

List of Navidea Biopharmaceuticals, Inc. patents

List of Oncimmune patents

List of Pervasive Software patents

List of SBIR/STTR awards granted to Somewear

Patents where

Current Assignee

Name

is

Arcus Biosciences

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 11787762 Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha	Patent 11787762 was granted and assigned to Arcus Biosciences on October, 2023 by the United States Patent and Trademark Office.	Arcus Biosciences	Arcus Biosciences		United States Patent and Trademark Office	11787762	October 17, 2023
	‌ US Patent 11407712 Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2α	Patent 11407712 was granted and assigned to Arcus Biosciences on August, 2022 by the United States Patent and Trademark Office.	Arcus Biosciences	Arcus Biosciences		United States Patent and Trademark Office	11407712	August 9, 2022
	‌ US Patent 10239912 Modulators of 5′-nucleotidase, ecto and the use thereof	Patent 10239912 was granted and assigned to Arcus Biosciences on March, 2019 by the United States Patent and Trademark Office.	Arcus Biosciences	Arcus Biosciences		United States Patent and Trademark Office	10239912	March 26, 2019
	‌ US Patent 10981944 Modulators of 5′-nucleotidase, ecto and the use thereof	Patent 10981944 was granted and assigned to Arcus Biosciences on April, 2021 by the United States Patent and Trademark Office.	Arcus Biosciences	Arcus Biosciences		United States Patent and Trademark Office	10981944	April 20, 2021
	‌ US Patent 10399962 Azolopyrimidine for the treatment of cancer-related disorders	Patent 10399962 was granted and assigned to Arcus Biosciences on September, 2019 by the United States Patent and Trademark Office.	Arcus Biosciences	Arcus Biosciences		United States Patent and Trademark Office	10399962	September 3, 2019
	‌ US Patent 11649261 Crystalline forms of a CD73 inhibitor and uses thereof	Patent 11649261 was granted and assigned to Arcus Biosciences on May, 2023 by the United States Patent and Trademark Office.	Arcus Biosciences	Arcus Biosciences		United States Patent and Trademark Office	11649261	May 16, 2023
	‌ US Patent 11001603 Modulators of 5′-nucleotidase, ecto and the use thereof	Patent 11001603 was granted and assigned to Arcus Biosciences on May, 2021 by the United States Patent and Trademark Office.	Arcus Biosciences	Arcus Biosciences		United States Patent and Trademark Office	11001603	May 11, 2021
	‌ US Patent 11058704 Inhibitors of adenosine 5′-nucleotidase	Patent 11058704 was granted and assigned to Arcus Biosciences on July, 2021 by the United States Patent and Trademark Office.	Arcus Biosciences	Arcus Biosciences		United States Patent and Trademark Office	11058704	July 13, 2021
	‌ US Patent 11045472 Quinazoline-pyridine derivatives for the treatment of cancer-related disorders	Patent 11045472 was granted and assigned to Arcus Biosciences on June, 2021 by the United States Patent and Trademark Office.	Arcus Biosciences	Arcus Biosciences		United States Patent and Trademark Office	11045472	June 29, 2021
	‌ US Patent 11220492 Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders	Patent 11220492 was granted and assigned to Arcus Biosciences on January, 2022 by the United States Patent and Trademark Office.	Arcus Biosciences	Arcus Biosciences		United States Patent and Trademark Office	11220492	January 11, 2022
	‌ US Patent 11478479 Dosing with an azolopyrimidine compound	Patent 11478479 was granted and assigned to Arcus Biosciences on October, 2022 by the United States Patent and Trademark Office.	Arcus Biosciences	Arcus Biosciences		United States Patent and Trademark Office	11478479	October 25, 2022
	‌ US Patent 11633416 Oral formulations of CD73 compounds	Patent 11633416 was granted and assigned to Arcus Biosciences on April, 2023 by the United States Patent and Trademark Office.	Arcus Biosciences	Arcus Biosciences		United States Patent and Trademark Office	11633416	April 25, 2023
	‌ US Patent 11267845 Inhibitors of CD73-mediated immunosuppression	Patent 11267845 was granted and assigned to Arcus Biosciences on March, 2022 by the United States Patent and Trademark Office.	Arcus Biosciences	Arcus Biosciences		United States Patent and Trademark Office	11267845	March 8, 2022
	‌ US Patent 12103907 Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha	Patent 12103907 was granted and assigned to Arcus Biosciences on October, 2024 by the United States Patent and Trademark Office.	Arcus Biosciences	Arcus Biosciences		United States Patent and Trademark Office	12103907	October 1, 2024
	‌ US Patent 11931343 CD73 inhibitors	Patent 11931343 was granted and assigned to Arcus Biosciences on March, 2024 by the United States Patent and Trademark Office.	Arcus Biosciences	Arcus Biosciences		United States Patent and Trademark Office	11931343	March 19, 2024
	‌ US Patent 12064433 Pyridone A2R antagonists	Patent 12064433 was granted and assigned to Arcus Biosciences on August, 2024 by the United States Patent and Trademark Office.	Arcus Biosciences	Arcus Biosciences		United States Patent and Trademark Office	12064433	August 20, 2024
	‌ US Patent 11667662 Modulators of 5′-nucleotidase, ecto and the use thereof		Arcus Biosciences	Arcus Biosciences		United States Patent and Trademark Office	11667662	June 6, 2023
	‌ US Patent 11993584 Solid forms of an azolopyrimidine compound	Patent 11993584 was granted and assigned to Arcus Biosciences on May, 2024 by the United States Patent and Trademark Office.	Arcus Biosciences	Arcus Biosciences		United States Patent and Trademark Office	11993584	May 28, 2024
	‌ US Patent 12071411 Inhibitors of HIF-2α and methods of use thereof	Patent 12071411 was granted and assigned to Arcus Biosciences on August, 2024 by the United States Patent and Trademark Office.	Arcus Biosciences	Arcus Biosciences		United States Patent and Trademark Office	12071411	August 27, 2024

19 results

0 selected

19 results

0 selected